<p>In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not </p>